A NEW STUDY FORPeople Living With Advanced or Metastatic Neuroendocrine Tumors
About STELLAR-311
STELLAR-311 is a The purpose of the study is to find out how a (zanzalintinib) works compared to an approved drug (everolimus) as a potential treatment for neuroendocrine tumors that cannot be removed by surgery or have spread to other parts of the body (metastatic).
Research studies help scientists and doctors learn more about medical conditions and study drugs. This study will help researchers learn if the study drug is safe and if it works to treat neuroendocrine tumors in many different types of people.
Contact Us
Call Exelixis Medical Information at 1-888-393-5494 (toll-free) or 1-303-389-1847, or email medinfo@exelixis.com to learn more about this study.
Who Can Join the STELLAR‑311 Study?
People with neuroendocrine tumors may be able to take part in STELLAR-311 if they:
- Are 18 years of age or older
- Have a neuroendocrine tumor that cannot be removed by surgery or that continues to grow or spread
- Have had no more than 1 treatment for a neuroendocrine tumor
There are other eligibility requirements you must meet to join the study. Download the STELLAR-311 Discussion Guide for key questions to help you talk with your doctor and decide if this study is right for you.
Talk with your doctor to learn if this study may be an option for you.
Discussion Guide
(Questions for your doctor)
To find out more about participating in the STELLAR-311 study, download the Discussion Guide with questions that can help you and your doctor decide if this study is right for you.
Participation = Representation
It is important that diverse groups of people take part in research studies. Studies should include people of different ages, sexes, races, and ethnicities. Having diverse groups represented in research helps show if study drugs are safe and work well for all types of people likely to use the drug(s).
People from different backgrounds can experience the same disease differently. Diversity in research studies can help us understand and address these types of differences.
Learn More About the Study
People enrolled in STELLAR-311 will be randomly assigned to one of two treatment groups by chance. Each group will receive either the study drug or everolimus. People will know which group they are assigned to and which study drug they will receive.
Volunteering for a study is a personal choice. We encourage people from all backgrounds to consider joining the STELLAR-311 clinical trial. Talk with a healthcare professional you trust about clinical trials as a treatment option.
Group A
People in this group will receive the study drug: zanzalintinib.
Group B
People in this group will receive a medicine approved for neuroendocrine tumors: everolimus.
People in the study will be assigned to a treatment group. One group will receive the study drug zanzalintinib and the other group will receive the standard treatment of everolimus.
A computer will randomly assign each person to a treatment group by chance:
Group A will get zanzalintinib.
Group B will get everolimus.
ZANZALINTINIB HAS NOT BEEN APPROVED BY REGULATORY AUTHORITIES. THE SAFETY AND EFFECTIVENESS OF ZANZALINTINIB HAVE NOT BEEN ESTABLISHED AND ARE BEING STUDIED AS PART OF THIS CLINICAL TRIAL.
Frequently Asked Questions
If this is the first time you are thinking of taking part in a clinical research study, you may have questions. Our FAQs may help answer them.
ClinicalTrials.gov
Find out more about STELLAR-311 on ClinicalTrials.gov. Search for NCT06943755.
Is There a Clinical Study Site Near Me?
STELLAR-311 will take place in the U.S. and abroad. For specific location and site information, and to confirm whether sites near you are still enrolling new participants, call 1-888-393-5494 (toll-free) or 1-303-389-1847, or email medinfo@exelixis.com.
Cities with currently open or planned study sites:
Study sites may start or stop enrolling patients at any time. Please check back if you do not see a study site located near you.
Please check www.clinicaltrials.gov for a list of the latest study sites.
Resources
The following third-party sites can provide information and resources for people living with neuroendocrine tumors that are advanced, cannot be removed, or have spread. They provide educational materials, including webinars and participant guides, and information about support groups.
National Comprehensive Cancer Network® (NCCN®)
The NCCN is dedicated to defining and advancing quality, effective, equitable, and accessible cancer care and prevention so all people can live better lives.
Neuroendocrine Cancer Foundation (NCF)
The NCF aims to improve the quality of life of those with neuroendocrine cancer by offering support and expanded access to information on diagnosis, treatment options, research, and resources.
Neuroendocrine Tumor Research Foundation (NETRF)
The NETRF is committed to improving the lives of patients, families, and caregivers affected by neuroendocrine cancer by providing information and educational resources.
ZANZALINTINIB HAS NOT BEEN APPROVED BY REGULATORY AUTHORITIES. THE SAFETY AND EFFECTIVENESS OF ZANZALINTINIB HAVE NOT BEEN ESTABLISHED AND ARE BEING STUDIED AS PART OF THIS CLINICAL TRIAL.